The use of immune competent mouse tumor models is critical to observe that response and accurately evaluate the efficacy of dual therapies targeting CDK4/6 and MEK, such as palbociclib plus mirdametinib (Figure 1). The gene discussed is CDK4; the disease is neoplasm.